Your browser doesn't support javascript.
loading
Improving mAb capture productivity on batch and continuous downstream processing using nanofiber PrismA adsorbents.
Davis, Ryan R; Suber, Fletcher; Heller, Ian; Yang, Boxuan; Martinez, Juan.
Afiliación
  • Davis RR; Ology Bioservices, Process Development, 13200 NW Nano Ct., Alachua, FL, 32615, USA.
  • Suber F; Ology Bioservices, Process Development, 13200 NW Nano Ct., Alachua, FL, 32615, USA.
  • Heller I; Ology Bioservices, Process Development, 13200 NW Nano Ct., Alachua, FL, 32615, USA.
  • Yang B; Ology Bioservices, Process Development, 13200 NW Nano Ct., Alachua, FL, 32615, USA.
  • Martinez J; Ology Bioservices, Process Development, 13200 NW Nano Ct., Alachua, FL, 32615, USA. Electronic address: Juan.Martinez@ologybio.com.
J Biotechnol ; 336: 50-55, 2021 Aug 10.
Article en En | MEDLINE | ID: mdl-34118332
Improving productivity and decreasing costs for biotherapeutic agents has been a focal driving force in the manufacturing of biologics. Advances in upstream processes have been continuously outpacing the ability for downstream operations to purify biologics, especially monoclonal antibodies. Continuous chromatography has several benefits for biologic purification including automated control, decreased labor, improved productivity, and more consistent product attributes. The goal of this study was to improve productivity and decrease costs associated with batch-mode and continuous purification processes. Productivities using cellulose nanofibers with a protein A ligand offer greater than 30-fold higher productivities than their resin-based equivalents using periodic countercurrent technology with multiple column chromatography. The smaller columns needed for convective mass transfer, faster processing times, and decreased costs allow for a more efficient mAb capture step. Additionally, high throughput purification (grams of mAbs/day) can be achieved from the scale-down model developed using periodic countercurrent technology. These advancements will help drive the evolution of downstream operations to manage the higher workloads due to increased upstream titers in a cost-effective manner.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Productos Biológicos / Nanofibras Idioma: En Revista: J Biotechnol Asunto de la revista: BIOTECNOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Productos Biológicos / Nanofibras Idioma: En Revista: J Biotechnol Asunto de la revista: BIOTECNOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos